Skip to content

A Trial Comparing Combined Spinal- Epidural Dosing Strategies for External Cephalic Version

A Randomized Controlled Trial Comparing Combined Spinal- Epidural Dosing Strategies for External Cephalic Version

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01991743
Enrollment
240
Registered
2013-11-25
Start date
2011-05-31
Completion date
2017-01-31
Last updated
2020-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Pregnancy

Keywords

Version, Pregnancy, Vaginal Delivery, Pain Control, Combined Spinal Epidural

Brief summary

We plan to conduct a prospective, single blinded, randomized clinical trial to assess the impact of combined spinal-epidural dosing on the success rate of, and patient satisfaction during, external version for breech fetal position and the incidence of vaginal vs. Cesarean delivery. The research aim of this project is to determine the ideal neuraxial dosing strategy to maximize success of external cephalic version (ECV). The research questions, does a combined spinal-epidural (CSE) of a higher dose result in greater success in converting a breech presentation to vertex during external cephalic version (ECV). The hypotheses of this project is that CSE at higher dose will result in greater ECV success than analgesic dosing. The research significance:Increasing the success and comfort of ECV for fetal malpresentation may help decrease the cesarean section rate.

Detailed description

At term 2 to 3% of singleton pregnancies are in breech presentation. Many of these deliveries are managed by cesarean delivery due to higher neonatal morbidity associated with vaginal breech delivery. However, cesarean delivery, the safer option for the baby, is associated with a higher incidence of maternal complications for both the current and subsequent pregnancies. External cephalic version (ECV) is a procedure commonly used to attempt to manually rotate the fetus into vertex position. This facilitates vaginal delivery and thus avoids higher maternal and/or neonatal complications. (Hofmeyr Cochrane Review) Obstetricians generally perform versions after 36 weeks gestational age with a reportable success rate of 50-80%, depending on several factors, including patient characteristics. (Fortunato, Zhang, ACOG 1997 ECV) The most common technique involves external manipulation of the fetal position preceded by pharmacologic uterine relaxation. Until recently, pain relief was generally provided in the form of intravenous opioids such as fentanyl. A more efficacious form of analgesia is the use of neuraxial opioids and local anesthetics (neuraxial analgesia), a technique commonly used for labor and delivery analgesia. Two non-randomized studies of neuraxial analgesia compared to systemic analgesia found improved success of external cephalic version in the neuraxial analgesia groups.(Carlan, Birnbach) Three randomized trials have conflicting results: 2 demonstrate an increase in success, one shows no difference. (Dugoff, Schorr, Mancuso) None of these studies have blinded the obstetrician performing the version. In 2010, Lavoie and colleagues completed a meta-analysis looking at ECV performed under analgesic and anesthetic neuraxial doses. The analgesic dose included spinal bupivacaine and epidural dosing. The anesthestic groups gave higher doses of spinal or epidural bupivacaine. This meta-analysis suggested that those patients who had received an anesthetic dose of had more successful ECV. All published studies examining pain outcomes have demonstrated that neuraxial analgesia results in greater patient comfort during this procedure. The American College of Obstetricians and Gynecologists (ACOG) has stated, Currently there is not enough evidence to make a recommendation favoring or opposing anesthesia during ECV (external cephalic version) attempts.

Interventions

DRUGGroup 2.5

Administration of bupivacaine 2.5 mg.

Administration of 5 mg bupivacaine

DRUGGroup 7.5

Administration of 7.5 mg bupivacaine

DRUGGroup 10

Administration of 10mg bupivacaine.

Sponsors

Northwestern University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Healthy patients age 18 and older * Breech presentation * Singleton gestation .scheduled for ECV desiring CSE.

Exclusion criteria

* Refusal * Contraindication to neuraxial (coagulopathy, anticoagulant use, local infection, sepsis etc) .Rupture of membranes. * Drop-out: Patients may choose to drop-out of the study at any time. The physicians involved in this study may choose to end a patient's involvement in the study at their discretion.

Design outcomes

Primary

MeasureTime frameDescription
Success Rate of External Cephalic VersionCompletion of the procedureRates of successful version evaluated among the 4 dose groups.

Secondary

MeasureTime frameDescription
Mode of DeliveryTo time of delivery
Indication of Cesarean DeliveryTo time of delivery
Pain Score During the Procedure< 20 minutespain score during the procedure (Visual Analog Score: VAS=0 no pain -100 worst pain imaginable, scale)
Abdominal Relaxation<20 minutesObstetrician rating of participants abdominal relaxation (Visual analog score: VAS score= 0 no relaxation- complete relaxation 100)

Countries

United States

Participant flow

Recruitment details

A total of 240 patients were enrolled and allocated to one of four bupivicaine dose groups

Participants by arm

ArmCount
Drug:Group 2.5
Administration of 2.5 mg bupivacaine Group 2.5: Administration of bupivacaine 2.5 mg.
60
Group 5
Administration of 5 mg bupivacaine. Group 5: Administration of 5 mg bupivacaine
60
Group 7.5
Administration of 7.5mg bupivacaine. Group 7.5: Administration of 7.5 mg bupivacaine
59
Group 10
Administration of 10 mg bupivacaine. Group 10: Administration of 10mg bupivacaine.
60
Total239

Withdrawals & dropouts

PeriodReasonFG000FG001FG002FG003
Overall Studyexternal cephalic version not performed0010

Baseline characteristics

CharacteristicDrug:Group 2.5Group 5Group 7.5Group 10Total
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
60 Participants60 Participants59 Participants60 Participants239 Participants
BMI29 kg/m^227 kg/m^228 kg/m^229 kg/m^228.5 kg/m^2
Duration of Procedure7 minutes7 minutes11 minutes8 minutes7 minutes
Estimated Gestational Age263 days261 days261 days261 days261 days
Sex: Female, Male
Female
60 Participants60 Participants59 Participants60 Participants239 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants0 Participants0 Participants
Sex/Gender, Customized
Female
60 Participants60 Participants59 Participants60 Participants239 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
0 / 600 / 600 / 590 / 60
other
Total, other adverse events
0 / 600 / 600 / 600 / 60
serious
Total, serious adverse events
0 / 600 / 600 / 590 / 60

Outcome results

Primary

Success Rate of External Cephalic Version

Rates of successful version evaluated among the 4 dose groups.

Time frame: Completion of the procedure

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Drug:Group 2.5Success Rate of External Cephalic Version31 Participants
Group 5Success Rate of External Cephalic Version31 Participants
Group 7.5Success Rate of External Cephalic Version31 Participants
Group 10Success Rate of External Cephalic Version30 Participants
Secondary

Abdominal Relaxation

Obstetrician rating of participants abdominal relaxation (Visual analog score: VAS score= 0 no relaxation- complete relaxation 100)

Time frame: <20 minutes

ArmMeasureValue (MEDIAN)
Drug:Group 2.5Abdominal Relaxation78 units on a scale
Group 5Abdominal Relaxation83 units on a scale
Group 7.5Abdominal Relaxation84 units on a scale
Group 10Abdominal Relaxation88 units on a scale
Secondary

Indication of Cesarean Delivery

Time frame: To time of delivery

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Drug:Group 2.5Indication of Cesarean DeliveryArrest of LAbor4 Participants
Drug:Group 2.5Indication of Cesarean DeliveryEmergency2 Participants
Drug:Group 2.5Indication of Cesarean DeliveryMalposition27 Participants
Drug:Group 2.5Indication of Cesarean DeliveryNonreassuring Fetal Status1 Participants
Group 5Indication of Cesarean DeliveryMalposition26 Participants
Group 5Indication of Cesarean DeliveryEmergency3 Participants
Group 5Indication of Cesarean DeliveryArrest of LAbor4 Participants
Group 5Indication of Cesarean DeliveryNonreassuring Fetal Status4 Participants
Group 7.5Indication of Cesarean DeliveryMalposition25 Participants
Group 7.5Indication of Cesarean DeliveryEmergency1 Participants
Group 7.5Indication of Cesarean DeliveryNonreassuring Fetal Status3 Participants
Group 7.5Indication of Cesarean DeliveryArrest of LAbor2 Participants
Group 10Indication of Cesarean DeliveryEmergency2 Participants
Group 10Indication of Cesarean DeliveryArrest of LAbor4 Participants
Group 10Indication of Cesarean DeliveryNonreassuring Fetal Status5 Participants
Group 10Indication of Cesarean DeliveryMalposition25 Participants
Secondary

Mode of Delivery

Time frame: To time of delivery

ArmMeasureGroupValue (NUMBER)
Drug:Group 2.5Mode of DeliveryVaginal26 count of participants
Drug:Group 2.5Mode of DeliveryCesarean34 count of participants
Group 5Mode of DeliveryCesarean37 count of participants
Group 5Mode of DeliveryVaginal23 count of participants
Group 7.5Mode of DeliveryVaginal28 count of participants
Group 7.5Mode of DeliveryCesarean31 count of participants
Group 10Mode of DeliveryVaginal24 count of participants
Group 10Mode of DeliveryCesarean36 count of participants
Secondary

Pain Score During the Procedure

pain score during the procedure (Visual Analog Score: VAS=0 no pain -100 worst pain imaginable, scale)

Time frame: < 20 minutes

ArmMeasureValue (MEDIAN)
Drug:Group 2.5Pain Score During the Procedure12 units on a scale
Group 5Pain Score During the Procedure5 units on a scale
Group 7.5Pain Score During the Procedure4 units on a scale
Group 10Pain Score During the Procedure4 units on a scale

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026